The pioneer in developing therapeutic filtration devices to address infectious disease and cancer.

Further evaluation of the captured exosomes is possible through detection molecules such as for example antibodies connected to a particular biomarker on the exosome.. Aethlon Medical files provisional patent with respect to ESI for exosome recognition assay Aethlon Medical, Inc. , the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it offers filed a provisional patent on behalf of its wholly possessed subsidiary Exosome Sciences, Inc. , relating to the advancement of an assay that will allow researchers to detect exosomes in blood and other fluids. Beyond the potential therapeutic benefits of eliminating immunosuppressive exosomes from circulation, experts understand that exosomes represent a significant diagnostic target to determine progression and prognosis of both cancers and infectious disease circumstances.Wilson, a previous undergraduate student in the UGA Honors program who’s now pursing graduate research at Emory University; Shyamala Mruthinti, research pharmacologist at the VA INFIRMARY and adjunct professor at MCG; and Jerry Buccafusco, director of the MCG Alzheimer’s Research Center. The team focused on antibodies that the body produces in response to two proteins that are associated with Alzheimer’s disease. One protein, known as amyloid-beta, forms the plaques that are evident in the brains of individuals with Alzheimer’s upon autopsy.